论文部分内容阅读
采用ＥＬＩＳＡ双抗体夹心法对２８例膀胱癌（膀胱癌组）、６例腺性膀胱炎（膀胱炎组）、１２例前列腺增生症（ＢＰＨ）患者（ＢＰＨ组）和２０例健康人（健康组）的血清，尿液及组织中可溶性白细胞介素－２受体（ＳＩＬ－２Ｒ）水平进行测定。结果表明，膀胱癌组血清ＳＬ－２Ｒ水平明显高于各对照组（Ｐ＜０．００１），尿中ＳＬ－２Ｒ水平比较，差异无显著性；而膀胱癌组织中ＳＬ－２Ｒ水平低于ＢＰＨ膀胱组织中ＳＩＬ－２Ｒ水平（Ｐ＜０．０５）；但在膀胱癌各分期、分级之间以及膀胱癌组手术前后血清、尿液中ＳＩＬ－２Ｒ水平差异无显著性意义，故认为血清ＳＬ－２Ｒ测定可作为膀胱癌早期诊断的辅助手段。
28 cases of bladder cancer (bladder cancer group), 6 cases of cystitis glandularis (cystitis group), 12 cases of benign prostatic hyperplasia (BPH) (BPH group) and 20 healthy people (healthy group ) Serum, urine and tissue soluble interleukin-2 receptor (SIL-2R) levels were measured. The results showed that the serum level of SL-2R in bladder cancer was significantly higher than that of the control (P <0.001), while the level of SL-2R in urine was not significantly different. However, the level of SL-2R in bladder cancer was lower than that of BPH (P <0.05). However, there was no significant difference in the levels of SIL-2R in serum and urine before and after operation among bladder cancer staging and grading, as well as bladder cancer -2R assay can be used as an early diagnosis of bladder cancer as an adjunct.